The Sunday Brief

Issue №36 · August 31, 2026

The most useful number this week is a rate: about one kilogram per month. That is how fast body weight returns after stopping semaglutide or tirzepatide, according to a meta-analysis pooling six studies and 1,776 participants — half the lost weight back by roughly 7.5 months, and the starting weight by about 15. For anyone modeling these drugs as a finite course rather than an open-ended commitment, this is the clearest timetable published so far.

Issue №33 · August 10, 2026

The week's most consequential result comes from inside SURMOUNT-1: a new analysis of stored blood samples from about 400 participants found large, dose-dependent drops in inflammatory and metabolic risk markers over 72 weeks of tirzepatide. It is the clearest evidence yet that the drug's cardiovascular story extends beyond the scale — though biomarkers and modeled risk scores remain stand-ins for counted heart events, and the field still owes readers dedicated outcome trials.

Issue №32 · August 3, 2026

The week's most consequential readout is a prespecified pooled analysis of individual patient data from SELECT, FLOW, and SOUL — nearly 31,000 people — in which semaglutide was associated with a 16% lower likelihood of a serious kidney endpoint over roughly three to four years. That matters because kidney protection has largely been inferred from single trials in narrower populations; pooling three placebo-controlled trials at the patient level moves it from suggestive to substantial, across both injectable and oral dosing.

Issue №31 · July 27, 2026

This week's evidence leans human and pooled: a meta-analysis of four randomized trials puts semaglutide's weight-loss advantage at roughly 11.85% over placebo in non-diabetic adults, while two phase 3 CagriSema trials and a network meta-analysis broaden the incretin picture in type 2 diabetes. Against that, a real-world adverse-event analysis raises an optic-nerve safety question worth reading carefully — the data can flag a cluster, not establish cause.

Issue №30 · July 20, 2026

The week's clearest signal came from a meta-analysis of placebo-controlled semaglutide trials in fatty liver disease, which reported reductions in liver enzymes and higher odds of NASH resolution while leaving the effect on fibrosis uncertain. That human, pooled-trial evidence is what a serious reader should weight most heavily this week — more than a single mouse study on bone that is drawing outsized community attention, and more than a compounding-committee vote that has been widely misread as a final FDA decision.

Issue №29 · July 13, 2026

This week's clearest signal came from a phase 2 randomised trial in metabolic steatohepatitis: adding zalfermin to semaglutide did not improve liver fibrosis over placebo, while semaglutide alone showed a nominally significant improvement. It is a useful reminder that combination logic does not always beat the simpler regimen, and that the strongest human evidence this week points to the base therapy, not the novel add-on. Two large observational studies and a pharmacovigilance analysis fill in the safety and outcomes picture around GLP-1 and dual agonists.

Issue №28 · July 6, 2026

The strongest single result this week is a randomized one. In a SURMOUNT-5 subpopulation analysis, tirzepatide was associated with about 20% body-weight loss over 72 weeks versus about 13% for semaglutide, with similar side-effect profiles reported. Around it sits a cluster of large observational studies on fractures, cardiovascular outcomes, and neuropsychiatric risk that strengthen the picture without settling it. All of this arrives just as the FDA's PCAC peptide docket closes for public comment ahead of its July 23–24 meeting.

The Sunday Brief · June 29, 2026

The week's center of gravity is regulatory. On July 23-24, an FDA advisory committee will weigh whether seven peptides — among them BPC-157, TB-500, and MOTS-C — belong on the 503A compounding list, the clearest signal yet of where legal access may settle. In parallel, the FDA is testing a theory that a product page describing physiological effects establishes drug intent, 'research use only' label notwithstanding. Together they mark a market moving from gray-zone tolerance toward defined rules.